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Abstract: Background: Clinically used antibiotics act through one of these four mechanisms: cell wall 
biosynthesis inhibition, inhibition of protein biosynthesis, interference with DNA and RNA synthesis 
and the folate pathway.  
Objective: The metalloenzymes carbonic anhydrases (CAs, EC 4.2.1.1) widespread in microorganisms 
and present as three genetically distinct families may be considered for the design of antiinfective agents 
with a different mechanism of action compared to the clinically used antibiotics. CAs are crucial for the 
life cycle of the pathogen, interfering with pH regulation and biosynthetic processes in which CO2 or 
bicarbonate are substrates. CA inhibition was shown to lead to debilitation or growth defects of several 
pathogenic bacteria.  
Method: CAs catalyzes the interconversion between carbon dioxide to bicarbonate, leading to the for-
mation of protons, and thus affecting pH homeostasis. Several classes of CA inhibitors (CAIs) are 
known to date, among which the metal complexing anions, the unsubstituted sulfonamides, the dithio-
carbamates, etc., which bind to the Zn(II) ion of the enzyme either by substituting the non-protein zinc 
ligand or add to the metal coordination sphere.  
Results: Effective inhibitors for many bacterial CAs belonging to the α-, β-, and γ-CA classes were de-
tected, some of which inhibited bacterial growth in vivo. Few of the inhibitors investigated so far were 
also selective for the bacterial over the human CA isoforms, which may pose problems for their wide 
clinical applications.  
Conclusion: Structure-based drug design campaigns might lead to the achievement of the desired selec-
tivity/potency for preferentially inhibiting bacterial but not the host CAs. 
Keywords: Carbonic anhydrase, Hydratase activity, Metalloenzymes, CA inhibitors, Pathogens, Selective inhibition, Antibac-
terial, Antiinfective, Sulfonamide, Anions, Inhibitor selectivity, Drug-design.  
1. INTRODUCTION 
1.1. Carbonic Anhydrases 
Carbonic anhydrases (CAs, EC 4.2.1.1) are ubiquitous 
metalloenzymes that catalyze the reversible hydration of 
carbon dioxide with the production of bicarbonate and pro-
tons [1-4]. The CA classification uses Greek letters for the 
designation of the seven CA families known to date, i.e., the 
α, β, γ, δ, ζ η and θ-CAs [5-10]. Detailed biochemical, ki-
netic, phylogenetic and structural studies afforded a clear 
view regarding the differences between CA families. The  
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catalytic function of CO2 hydration is maintained for all CA 
classes, despite the diverse spatial reorganization of the ac-
tive sites [5,
 
11-16]. In general the catalytic efficiency of the 
γ-, δ- and ζ-CAs is low compared to the β- and η-CAs, 
which in turn are less efficient catalysts compared to many 
bacterial α-CAs [6,
 
9,
 
11,
 
17]. Interestingly, γ-CAs use only 
CO2 as substrate, while β-CAs can hydrolyze CO2, H2S and 
COS [18]. Furthermore, α-CAs not only hydrate CO2, CS2 
but also possess esterase activity, with a range of esters of 
carboxylic, sulfonic or phosphate acids [6,
 
9,
 
11,
 
17,
 
19,
 
20]. 
Generally, bacterial genome encodes for three CA classes 
that in agreement with the CA family nomenclature are de-
signed as α, β and γ [17]. CAs distribution pattern in bacteria 
is very intriguing [17]. In bacteria, CAs belonging to one 
class, two or three different genetic families were evidenced, 
whereas in few of them no CAs seem to be present, i.e., 
Gram-negative bacteria of the genera Buchnera and Rick-
ettsia [17]. The evolutionary relationship of CAs from pro-
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karyotes is thus characterized by a high degree of complex-
ity, not entirely understood at the present time.  
Recently, we investigated the diverse CAs present in the 
genome of thermophilic and psychrophilic bacteria, whereas 
in mesophilic bacteria their presence was investigated for 
some species in the last 15 years  [7-9,
 
12,
 
13,
 
17,
 
21-24]. The 
metal ion from the enzyme active site is coordinated by three 
His residues in the α-, γ- ,δ- and θ-classes, by one His, and 
two Cys residues in β- and ζ-CAs or by two His and one Gln 
residues in η-class with the fourth ligand being a water 
molecule/hydroxide ion acting as nucleophile in the catalytic 
cycle of the enzyme [9,
 
12,
 
17,
 
25]. The α-, β-, δ- and, proba-
bly η- and θ-CAs use Zn(II) ions at the active site, γ-CAs are 
Fe(II) enzymes but they are active also with bound Zn(II) or 
Co(II) ions, whereas ζ-class uses Cd(II) or Zn(II) to perform 
the physiologic reaction catalysis [6,
 
9,
 
12,
 
17,
 
26,
 
27]. The α-
, β-, γ- and ζ-CAs have been crystallized, but not δ-, η- and 
θ-CAs. The three-dimensional structures of the different CA-
classes, e.g. the the overall shape of the molecules, the pro-
tein folding patterns as well as the oligomeric state, are very 
different for the three CA classes present in bacteria [8,
 
28]. 
For example, α-CAs are normally monomers and rarely 
dimmers; β-CAs are dimers, tetramers or octamers; γ-CAs 
are trimers; the only ζ-CA crystallized so far has three 
slightly different active sites on the same polypeptide chain 
[8,
 
28]. Phylogenetic analysis has shown that the most recent 
form is the α-CA class, whereas the γ-class is the most an-
cient CA class, catalyzing only CO2 hydration with a rather 
weak catalytic efficiency and is the only CA class mainly 
identified in Archaea, the most ancient microorganisms that 
exist on earth [6,
 
12,
 
17,
 
29]. 
1.2. CA Inhibitors  
Several classes of CA inhibitors (CAIs) are known to 
date: (i) the metal ion binders (anion, sulfonamides and their 
isosteres, dithiocarbamates, xanthates, etc, Fig. 1A); (ii) 
compounds which anchor to the zinc-coordinated water 
molecule/hydroxide ion (phenols, polyamines, thioxocou-
marins, sulfocoyumarins, etc., Fig. 1B); (iii) compounds oc-
cluding the active site entrance, such as coumarins and their 
isosteres – Fig. 1C, and (iv) compounds binding out of the 
active site, Fig. 1D [24,
 
30-33]. 
Few such compounds apart the anions, sulfonamides and 
dithiocarbamates were investigated so far for the inhibition 
of the bacterial CAs [12].  
1.2.1. Anions 
Anions, such as the inorganic metal-complexing ones or 
more complicated species such as the carboxylates, are also 
known to bind to the CAs, but generally with less efficiency 
compared to the sulfonamides [30,
 
34,
 
35]. Anions may bind 
either the tetrahedral geometry of the metal ion or as trigo-
nal–bipyramidal adducts, as shown (for the tetrahedral ge-
ometry in Fig. 1A). Anions are an important class of CAIs, 
which were useful for designing novel types of more com-
plex inhibitors possessing an organic scaffold, which af-
forded the discovery of totally new families of such pharma-
cologic agents [24,
 
36-42]. 
 
1.2.2. Sulfonamides 
The sulfonamides were the first antimicrobial drugs, dis-
covered in 1935 by Domagk, and they paved the way for the 
antibiotic revolution in medicine [43]. Prontosil, the first 
such derivative showing effective antibacterial action was in 
fact a prodrug, obtained by the bioreduction of prontosil with 
formation sulfanilamide, 4-aminobenzenesulfonamide. After 
this bacteriostatic agent, a range of analogs has entered into 
clinical use (constituting the so-called sulfa drug class of 
antibacterials), and many of these compounds are still widely 
used (Fig. 2) [44]. Derivative used clinically, among which 
acetazolamide, methazolamide, ethoxzolamide, dichloro-
phenamide, dorzolamide and brinzolamide, bind in a tetrahe-
dral geometry to the Zn(II) ion in deprotonated state (Fig. 
1A), with the nitrogen atom of the sulfonamide moiety coor-
dinated to Zn(II) and an extended network of hydrogen 
bonds, involving amino acid residues Thr199 and Glu106 
(numbering system used for the human CA, isoform I), also 
participating to the anchoring of the inhibitor molecule to the 
metal ion [44]. The aromatic/heterocyclic part of the inhibi-
tor interacts with hydrophilic and hydrophobic residues of 
the cavity.  
1.2.3. Dithiocarbamates 
Dithiocarbamates (DTCs) were discovered as a com-
pletely new class of CAIs only recently, after the investiga-
tion of some inorganic anions acting in this way [45-50]. 
Indeed, the simple inorganic compound trithiocarbonate 
(TTC, CS32-), [51] for which an X-ray crystal structure in 
complex with the isoform hCA II was available, showed that 
the inhibitor is bound to the Zn(II) ion from the enzyme cata-
lytic site through one of its three equivalent sulfur atoms, 
whereas a second such atom interacted with the conserved 
Thr199 amino acid residue. As the third sulfur did not make 
any interactions with the enzyme, the DTCs were synthe-
sized, in which the third sulfur is replaced with a nitrogen 
atom and organic scaffold. DTCs were shown to act as mi-
cromolar- low nanomolar CAIs against many CA isoforms 
as their organic scaffold participates in supplementary inter-
actions with the enzyme active site. These compounds were 
also investigated for the inhibition of some pathogenic CAs 
such as those of Mycobacterium tuberculosis, Porphyro-
monas gingivalis, etc. [1, 47, 52, 53]. The DTCs showed ef-
fective CA inhibitory activity against many bacterial en-
zymes (Fig. 3.)  
2. RESULTS AND DISCUSSION 
2.1. Carbonic Anhydrases and their Implication in Bac-
terial Virulence 
At present, infectious diseases are the second-leading 
cause of death in the world and the emergence of antibiotic-
resistant bacteria is an inevitable and widespread phenome-
non, inherent to most drugs [54,
 
55]. The possibility to de-
velop new antibacterial agents raised much interest recently. 
The main classes of antibiotics clinically used nowadays act 
towards the inhibition of four classical targets: a) cell wall 
biosynthesis; b) protein biosynthesis; c) DNA and RNA bio-
synthesis; d) folate biosynthesis [56]. Recently, carbonic 
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Fig. (1). CA inhibition mechanisms: A. Zinc-binding; B. Anchoring to the metal ion coordinated water; C. Occlusion of the active site en-
trance. D. Out of the active site binding. 
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Fig. (2). Sulfonamides investigated as inhibitors of bacterial CA 
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Fig. (3). Sulfonamides and dithiocarbamates 32-43 showing selec-
tive bacterial CA inhibitory properties. 
anhydrases (CAs, EC 4.2.1.1) started to be investigated in 
detail in pathogenic bacteria, in the search for antibiotics 
with a novel mechanism of action, since it has been demon-
strated that in many bacteria, CAs are essential for the life 
cycle of the microoorganism and that their inhibition leads to 
growth impairment or growth defects of the pathogen [24,
 
34,
 
57-59].  
2.1.1. Vibrio Cholerae  
The Gram-negative bacterium Vibrio cholerae is the 
causative agent of cholera [60-62]. The genome of V. chol-
erae encodes for putative CAs belonging to each bacterial 
class: α, β and γ. The α-CA has been cloned, purified, and 
characterized from our group and it was named VchCA [60-
62]. Recently, our group purified the recombinant α- and β-
CAs (named VchCA and VchCAβ, respectively) identified 
in the genome of this pathogenic bacterium. [60-63]VchCA 
was shown to possess a significant catalytic activity for the 
reaction that converts the CO2 to bicarbonate and protons, 
with a kcat of 8.23 x 10
5
 s-
1
 and a kcat/Km of 7.0 x 10
7
 M-
1
 x s-
1
 [61, 62], whereas VchCAβ had the following kinetic pa-
rameters: a kcat of 3.34 x 10
5
 s-
1
 and a kcat/Km of 4.1 x 10
7
 M-
1
 x s-
1
. [63]Moreover, our subsequent work allowed the crys-
tallization of VchCAβ, showing that the zinc ion is coordi-
nated by four amino acid residues, Cys42, Asp44, His98, 
Cys101, in an approximately tetrahedral geometry. VchCAβ 
belongs to the type II subclass β-CAs, characterized by four 
protein-derived ligands that coordinate the catalytic zinc ion, 
contrary to the type I β-CAs that have only two cysteines and 
one histidine residues in the zinc coordination sphere with a 
fourth coordination site occupied by a water mole-
cule/hydroxide ion acting as nucleophile in the catalytic cy-
cle [63]. The crystal structure was determined at pH 8.0, 
when a bicarbonate ion bound in a non-catalytic binding 
pocket close to the zinc ion was also observed [48]. At pH 
8.3, the enzyme showed a significant catalytic activity for 
the physiological reaction of CO2 hydration to bicarbonate 
and protons as demonstrated by the following kinetic pa-
rameters: kcat of 3.34 x 10
5
 s-
1
 and a kcat/Km of 4.1 x 10
7
 M-
1
x s-
1
 [63].This is in fact the situation for all type II β-CAs, 
which at pH values > 8 become of type I, with the asp resi-
due being involved in a salt bridge with a neighboring con-
served Arg, and an incoming water molecule/hydroxide ion 
replacing the Asp residue [49-54]. Recently it was reported 
that sodium bicarbonate induces cholera toxin (CT) expres-
sion [64,
 
65]. It was demonstrated that bicarbonate stimulates 
virulence gene expression by enhancing ToxT, a regulatory 
protein that directly activates transcription of the genes en-
coding CT activity [65]. Addition of CA inhibitors caused a 
significant reduction in virulence gene expression. Thus, 
bicarbonate was the first positive effector for ToxT activity 
to be identified. The bicarbonate ion is present at a high con-
centrations in the upper small intestine colonized by V. chol-
era suggesting that the potential of V. cholera CAs could be 
implicated in the microbial virulence [60-62].  
2.1.2. Helicobacter pylori 
Helicobacter pylori is a neutralophile with a bioenerget-
ics profile suited for growing at neutral pH. This pathogenic 
bacterium lives in the highly acidic environment of the 
stomach (pH = 2-3). Its genome encodes three CAs: one α-, 
one β-, and one γ-CA, respectively [66-70]. The α-CA was 
shown to possess a periplasmic localization, the β-CA has 
been found in the cytoplasm, whereas no information is 
available on the expression/localization of the H. pylori γ-
CA. H. pylori has developed exclusive adaptive mechanisms 
for growing in the highly acid environment of the stomach 
(pH between 1 and 2) [71]. These mechanisms involve the 
urease and the CA enzymes, which allow the bacteria to 
colonize the stomach by regulating the periplasmic pH and 
elevating the cytoplasmic pH trough the production of NH3. 
Under acidic conditions, urea goes into the cytoplasm 
through the urea channel [3]. In the bacteria cytoplasm 2NH3 
and CO2 are produced by hydrolysis of urea. CO2 in the cy-
toplasm is hydrated by the β-CA, while the CO2 that diffused 
into the periplasm is converted to HCO3-
 
by the periplasmic 
α-CA. The produced ions, such as H
+
 are used by NH3 to 
form NH4
+
 in the periplasm and cytoplasm, respectively [3]. 
Thus, as showed in (Fig. 1), the role of periplasmic α-CA 
and the cytoplasmic β-CA is to generate HCO3- and protons, 
to both neutralize entering acid and buffer the periplasm and 
the cytoplasm [3]. The crucial role played by these CAs pre-
sent in H. pylori is the acid acclimatization of the pathogen 
within the stomach [72,
 
73]. This role is corroborated by the 
in vivo inhibition studies carried out using inhibitors α and β-
CAs in H. pylori. The inhibition of these two enzymes, in 
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fact, led to the death of the bacteria and a possible eradica-
tion of H. pylori from the stomach and has been used clini-
cally for the treatment of gastric ulcers [66,
 
67].  
2.1.3. Other Pathogenic Bacteria 
CA enzymes were investigated in detail in other patho-
genic bacteria (see Tables 1 and 2). For some of them, X-ray 
crystal structures of the encoded CAs were also determined, 
and in vitro and in vivo inhibition studies with various 
classes of inhibitors, such as anions, sulfonamides and sul-
famates have been reported [3,
 
32,
 
74-78]. Although the bac-
terial CA inhibition studies are in their infancy at this mo-
ment, cloning of more bacterial genomes may lead to the 
discovery of genes and proteins which may have interesting 
applications both in the biomedical and biotechnological 
fields [3,
 
32,
 
44,
 
74,
 
75,
 
78]. 
2.1.4. Two Pathogenic Bacteria from the Oral Cavity, P. 
gingivalis and S. mutans 
Periodontal disease is a general term describing the in-
flammatory pathologic states of the supporting tissues of 
teeth, which can be grouped into two major categories, gin-
givitis and periodontitis. Gingivitis is defined as an inflam-
mation of gingival tissues without affecting the attachment 
of teeth, while periodontitis involves the destruction of the 
connective tissue attachment to the tooth and the adjacent 
alveolar bone [79,
 
80]. Chronic adult periodontitis is the 
most common form of advanced periodontal disease. The 
microbes involved are extremely diverse and may be com-
posed of more than 150 different species [81-83]. Among the 
bacteria regularly isolated from periodontal pockets, those 
producing such pathological states are generally gram-
negative rods and include mainly Porphyromonas gingivalis, 
and other such as Prevotella intermedia, Fusobacterium nu-
cleatum, Actinobacillus actinomycetemcomitans, Capnocy-
tophaga sputigena, and Wolinella recta [84, 85]. As many 
other bacteria, the genome of P. gingivalis encodes for both 
a β- and γ-CA named with the acronyms PgiCAβ and 
PgiCA, respectively [8,
 
22,
 
28,
 
86-91].  
Dental caries is a bacterial disease of the dental hard tis-
sues (teeth); it is characterized by a localized, progressive, 
molecular disintegration of the tooth structure [92, 93]. Car-
ies is associated with dental plaque of smooth coronal sur-
faces, pits, and fissures. Caries may also appear on root sur-
faces that are exposed to the oral environment as a result of 
gingival recession. The demineralization of teeth is caused 
by organic acid produced from the bacterial fermentation of 
carbohydrates present in the diet, which leads to a low pH 
(between 5.0 and 5.5) environment due to the selection of 
bacteria which are acid tolerating and capable of producing 
acid from carbohydrates [94, 95]. Among these bacteria, 
mutans streptococci, including Streptococcus mutans, Strep-
tococcus sobrinus, Streptococcus cricetus, and Streptococcus 
rattus, were shown to be the most cariogenic. For example, 
the increased growth of Streptococcus mutans leads to the 
production of acid at a higher rate, enhancing demineraliza-
tion of the tooth [94,
 
95]. In the genome of S. mutans a β-
CA-encoding gene, denominated SMU_328, has been identi-
fied and the protein, indicated was indicated with the acro-
nym SmuCA [96,
 
97].  
Enzymes belonging to the β- and γ-CA classes in these 
two pathogens have been cloned, expressed, purified and 
characterized. PgiCA, PgiCAb and SmuCA showed signifi-
cant catalytic activity for the physiologic reaction catalyzed 
by these enzymes, the hydration of carbon dioxide to bicar-
bonate and protons. Several inhibition studies with the main 
classes of classical CAIs, the anions and the sulfonamides, 
also led to the discovery of effective inhibitors belonging to 
both classes and directed towards all three enzymes [22,
 
28,
 
87,
 
91,
 
97]. Unfortunately, no in vivo inhibition of growth 
studies of the two pathogens in the presence of the CA in-
hibitors have been reported for the moment. 
2.2. CA Inhibition Studies  
2.2.1. VchCA and VchCAβ Sulfonamide Inhibition Studies 
Sulfonamides and their bioisosteres (sulfamates and sul-
famides) are the most investigated types of CA inhibitors. A 
library of 40 compounds, comprising 39 sulfonamides and 
one sulfamate (see Fig. 2), investigated earlier as inhibitors 
of α, β or γ class CAs, were tested as inhibitors of the CAs 
here described [3, 4, 44, 98-100]. Derivatives 1–24 and 
AAZ-HCT are either simple aromatic/heterocyclic sulfona-
mides widely used as building blocks for obtaining new 
families of such pharmacological agents, or clinically used 
agents, among which acetazolamide AAZ, methazolamide 
MZA, ethoxzolamide EZA and dichlorophenamide DCP are 
the classical, systemically acting antiglaucoma CA inhibitors 
(CAIs). Dorzolamide DZA and brinzolamide BRZ are topi-
cally acting antiglaucoma agents, benzolamide BZA is an 
orphan drug belonging to this class of pharmacological 
agents, whereas topiramate TPM, zonisamide ZNS and 
sulthiame SLT are widely used antiepileptic drugs. Sulpiride 
SLP and indisulam IND were also shown by our group to 
belong to this class of pharmacological agents, together with 
the COX2 ‘selective’ inhibitors celecoxib CLX and 
valdecoxib VLX. Saccharin and the diuretic hydrochlorothi-
azide HCT are also known to act as CAIs [3,
 
4,
 
44,
 
98-100]. 
2.2.1.1. VchCA 
A VchCA inhibition study with sulfonamides and sul-
famates led to the detection of a large number of low nano-
molar inhibitors, among which were methazolamide, aceta-
zolamide, ethoxzolamide, dorzolamide, brinzolamide, benzo-
lamide, and indisulam (KI values in the range 0.69−8.1 nM) 
[60,
 
62,
 
101,
 
102]. 
2.2.1.2. VchCAβ 
A similar sulfonamide inhibition study of the other en-
zyme cloned so far in V. cholerae, VchCAβ, led to the detec-
tion of a large number of low nanomolar inhibitors, among 
which are methazolamide, acetazolamide, ethoxzolamide, 
dorzolamide, brinzolamide, benzolamide, and indisulam (KI 
values in the range 0.69-8.1 nM). Since ethoxzolamide was 
shown to inhibit this virulence in vivo [62], we proposed that 
VchCA might be a target for antibiotic development. 
Moreover, The best VchCAβ inhibitors were deacetylated 
acetazolamide and methazolamide and hydrochlorothiazide, 
which showed inhibition constants of 68.2 – 87.0 nM. Other 
compound, with medium potency against VchCAβ, (KIs in 
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Table 1. CAs from pathogenic bacteria cloned, purified, characterized and subjected to extensive in vitro inhibition study. 
Inhibition study  Pathogen CA class Name 
Sulfonamides Anions 
Brucella suis β bsCA1 + - 
 β bsCA2 + - 
Vibrio cholerae α VchCA + + 
Helicobacter pylori α hpαCA + + 
 β hpβCA + + 
Mycobacterium tuberculosis β mtCA 1 + - 
 β mtCA 2 + - 
 β mtCA 3 + - 
Clostridium perfringens β CpeCA - + 
Neisseria gonorrhoeae α NgoCA + + 
Neisseria sicca α NsiCA + - 
Streptococcus pneumoniae β PCA + + 
Salmonella enterica β stCA1 + + 
 β stCA2 + + 
Haemophilus influenzae β HICA - + 
Porphyromonas gingivalis β PgiCAb - + 
 γ PgiCA + + 
Legionella pneumophila β LpCA1 + + 
 β LpCA2 + + 
Table 2. Disease and characteristic of infectious caused by the pathogenic bacterium to its host. 
Pathogen Disease Characteristic of infectious 
Brucella suis Brucellosis A highly contagious zoonosis caused by ingestion of unpasteurized milk or undercooked meat 
Vibrio Cholerae Cholera An infectious disease that causes severe watery diarrhea, which can lead to dehydration and even death 
if untreated. 
Helicobacter pylori Gastritis and 
gastric ulcers 
An inflammation of the lining of the stomach.  
Mycobacterium tuberculosis  Tuberculosis An infectious that attacks the lungs, but can also affects other parts of the body. 
Clostridium perfringens Food poison-
ing 
Depending on the type of infection, people can even die as a result of food poisoning. 
Neisseria gonorrhoeae Gonorrhea A common human sexually transmitted infection. 
Neisseria sicca Septicemia A potentially fatal whole-body inflammation 
Streptococcus pneumoniae Pneumonia  An inflammatory condition of the lung affecting primarily the microscopic air sacs known as alveoli. 
Salmonella enterica Salmonellosis An infection that develop diarrhea, fever, vomiting, and abdominal cramps 12 to 72 hours after infec-
tion. 
Haemophilus influenzae Influenza An infectious disease that can produce nausea and vomiting or gastroenteritis  
Porphyromonas gingivalis Periodontitis, 
rheumatoid 
arthritis  
A set of inflammatory diseases affecting the tissues that surround and support the teeth. Rheumatoid 
arthritis is an infectious often leading to the destruction of articular cartilage. 
Legionella pneumophila Legionellosis Is a form of pneumonia 
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the range of 275 – 463 nM), were sulfanilamide, metanila-
mide, sulthiame and saccharin whereas the clinically used 
agents such as acetazolamide, methazolamide, ethoxzola-
mide, dorzolamide, zonisamide and celecoxib were micro-
molar inhibitors (KIs in the range of 4.51 – 8.57 µM). Identi-
fication of potent and possibly selective inhibitors of VchCA 
and VchCAβ may lead to pharmacological tools useful for 
understanding the physiological role(s) of this under-
investigated enzyme [60-62]. 
2.2.2. VchCA Anion Inhibition Studies  
Many inorganic anions and several small molecules were 
investigated as VchCA inhibitors. Inorganic anions such as 
cyanate, cyanide, hydrogen sulfide, hydrogen sulfite, and 
trithiocarbonate were effective VchCA inhibitors with inhi-
bition constants in the range of 33-88μM. Other effective 
inhibitors were diethyldithiocarbamate, sulfamide, sul-
famate, phenylboronic acid and phenylarsonic acid, with KIs 
of 7-43μM. Halides (bromide, iodide), bicarbonate and car-
bonate were much less effective VchCA inhibitors, with KIs 
in the range of 4.64-28.0mM. The resistance of VchCA to 
bicarbonate inhibition may represent an evolutionary adapta-
tion of this enzyme to living in an environment rich in this 
ion, such as the gastrointestinal tract, as bicarbonate is a 
virulence enhancer of this bacterium. 
2.2.3. hpαCA and hpβCA Sulfonamide Inhibition Studies 
2.2.3.1. hpαCA 
Dorzolamide and simple 4-substituted benzenesulfona-
mides were weak hpCA inhibitors (inhibition constants, 
K(I)s, in the range of 830-4310 nM). [103,
 
104] Sulfanila-
mide, orthanilamide, some of their derivatives, and indisu-
lam showed better activity (K(I)s in the range of 310-562 
nM), whereas most of the clinically used CA inhibitors, such 
as methazolamide, ethoxzolamide, dichlorophenamide, brin-
zolamide, topiramate, zonisamide, etc., acted as medium 
potency hpCA inhibitors (K(I)s in the range of 124-287 nM)
 
 
[70] .Some potent hpCA inhibitors were detected too (K(I)s 
in the range of 20-96 nM) such as acetazolamide, 4-amino-6-
chloro-1,3-benzenedisulfonamide, 4-sulfanilyl-aminoethyl-
benzenesulfonamide, and 4-(2-amino-pyrimidin-4-yl)-
benzenesulfonamide [70] . 
2.2.3.2. hpβCA 
hpβCA was strongly inhibited (K(I)s in the range of 24-
45 nM) by many sulfonamides/sulfamates, among which 
acetazolamide, ethoxzolamide, topiramate, and sulpiride, all 
clinically used drugs. 
2.2.4. hpαCA and hpβCA Anion Inhibition Studies 
The gastric pathogen Helicobacter pylori encodes two 
carbonic anhydrases (CAs, EC 4.2.1.1), an α- and a β-class 
one, hpαCA and hpβCA, crucial for its survival in the acidic 
environment from the stomach. Sulfonamides, strong inhibi-
tors of these enzymes, block the growth of the pathogen, in 
vitro and in vivo.  
2.2.4.1. hpαCA 
hpαCA was inhibited in the low micromolar range by di-
ethyldithiocarbamate, sulfamide, sulfamic acid, phenylbo-
ronic acid, and in the submillimolar one by cyanide, cyanate, 
hydrogen sulfide, divanadate, tellurate, perruthenate, seleno-
cyanide, trithiocarbonate, iminodisulfonate. [105] 
2.2.4.2. hpβCA 
hpβCA generally showed a stronger inhibition with most 
of these anions, with several low micromolar and many 
submillimolar inhibitors detected. [105]These inhibitors may 
be used as leads for developing anti-H. pylori agents with a 
diverse mechanism of action compared to clinically used 
antibiotics. 
2.2.5. SmuCA, PgiCAb and PgiCA Sulfonamide Inhibition 
Studies 
2.2.5.1. SmuCA  
SmuCA was efficiently inhibited by most sulfonamides 
investigated so far (KIs of 246 nM–13.5 μM) – Table 3. The 
best SmuCA inhibitors were bromosulfanilamide 9, deacety-
lated acetazolamide 13, 4-hydroxybenzenesulfonamide 15, 
the pyrimidine-substituted sulfanilamide derivative 19, ami-
nobenzolamide 20 and compounds structurally similar to it, 
as well as acetazolamide, methazolamide, indisulam and 
valdecoxib. These compounds showed inhibition constants 
ranging between 246 and 468 nM [96, 97] (Table 3). 
2.2.5.2. PgiCAb 
Many of the clinically used sulfonamides as well as sim-
ple aromatic/heterocyclic sulfonamides were ineffective as 
PgiCAb inhibitors, whereas better inhibition was observed 
with simple derivatives such as metanilamide 1, 1,3-
Benzenedisulfonamide 3, 4-aminoethylbenzenesulfonamide 
5 (KIs of 364–477 nM). The halogenosulfanilamides incorpo-
rating heavy halogens (compounds 8-10), 4-hydroxy- and 4-
hydroxyalkyl-benzenesulfonamides (compounds 15-17) 
were ineffective PgiCAb inhibitors with KIs in the micromo-
lar range. The best inhibitors were AAZ and EZA, with KIs 
of 214–280 nM [22] (Table 3).  
2.2.5.3. PgiCA 
DCP, TPM and many simple aromatic/heterocyclic sul-
fonamides were ineffective as PgiCA inhibitors, whereas the 
best inhibition was observed with halogenosulfanilamides 
incorporating heavy halogens (compounds 9 and 10), 4-
hydroxy- and 4-hydroxyalkyl-benzenesulfonamide (com-
pounds 15-17), AAZ, MZA, ZNS, IND, CLX, SAC and 
HCT (KIs in the range of 131–380 nM) [22, 28, 87]. Moreo-
ver, novel quinazoline derivatives endowed with a sulfona-
mide functionality at position-2 were tested for their ability 
to inhibit PgiCA [90]. Six such compounds were highly ef-
fective, nanomolar inhibitors of the pathogenic enzyme. 
Three of them were also highly effective sub-nanomolar in-
hibitors of the cytosolic human isoform II (hCA II). The best 
PgiCA inhibitor was a compound with KI of 3.53 nM against 
the bacterial enzyme. Many of these new compounds 
showed a high selectivity for bacterial enzyme respect to the 
mammalian CA isoforms hCA I and hCA II [22, 28, 87] 
(Table 3). 
2.2.6. SmuCA, PgiCAb and PgiCA Anion Inhibition Stud-
ies 
Inhibition data of the three CAs from the pathogenic bac-
teria of the oral cavity with a range of inorganic/organic
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Table 3. Inhibition data and inhibitor selectivity of various compounds against human isoform hCA II (off-target) and bacterial 
CAs considered in the present paper. Inhibition data were obtained by a Stopped-Flow CO2 hydrase assay, while the in-
hibitor selectivity is represented by the human KI/bacterial KI ratio. For acronyms see Table 1. 
 KI Inhibitor selectivity versus hCA II 
Compound hCAII bsCA1 bsCA2 VchCA hpαCA hpβCA PCA bsCA1 bsCA2 VchCA hpαCA hpβCA PCA 
SLP 40 nM 19 nM - - - - - 2.10 - - - - - 
20  33 nM 21 nM - - - - - 1.57 - - - - - 
14  19 nM - 11.2 nM - - - - - 1.69 - - - - 
27  25 nM 9.2 nM 10.1 nM - - - - 2.71 2.47 - - - - 
IND 15 nM - - 8.1 nM - - - - - 1.85 - - - 
BZA 9 nM - - 4.2 nM - - - - - 2.14 - - - 
EZA 8 nM - - 0.69 nM - - - - - 11.59 - - - 
MZA 14 nM - - 3.6 nM - - - - - 3.88 - - - 
21 30 nM - - 4.7 nM - - - - - 6.38 - - - 
32  104 nM - - - 31 nM - - - - - 3.35 - - 
33  94 nM - - - 27 nM 45 nM - - - - 3.48 2.08 - 
34  127 nM - - - 62 nM 44 nM - - - - 2.04 2.88 - 
FSO3- 0.46 
mM 
- - - - - 0.060 mM - - - - - 7.6 
V2O72- 0.57 
mM 
- - - - - 0.038 mM - - - - - 15 
SeO4 2- 112 mM - - - - - 0.044 mM - - - - - 2545 
35 33.0 nM 4.7 nM - 2.6 nM - - - 7.02 - 14.34 - - - 
36 29.4 nM 6.0 nM - 3.6 nM - - - 4.9 - 8.16 - - - 
37 36.3 nM 7.1 nM - 2.8 nM - - - 5.11 - 12.96 - - - 
38 325 nM 7.8 nM - 8.3 nM - - - 41.66 - 30.15 - - - 
39 105 nM - 59 nM - - - - - 1.77 - - - - 
40 104 nM - 45 nM - - - - - 2.31 - - - - 
Et2NCS2- 3.1 mM - - - 0.36 mM - - - - - 8.61 - - 
SeO42- 112 mM - - - 0.47 mM - - - - - 238.29 - - 
H2NSO2NH2 1.13 
mM 
- - - 0.009 
mM 
- - - - - 125.55 - - 
PhAsO3H2 49.2 
mM 
- - - 0.007 
mM 
- - - - - 7028 - - 
AAZ 12 nM - - - - 59 nM 84 nM - - - - - - 
MZA 14 nM - - - - 134 nM 68 nM - - - - - - 
18  46 nM - - - - 91 nM 40 nM - - - - - 1.15 

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(Table 3) contd…. 
 KI Inhibitor selectivity versus hCA II 
Compound hCAII PgiCAb PgiCA LpCA1 LpCA2 PgiCAb PgiCA LpCA1 LpCA2 
PhAsO3H2 49.2 mM 0.076 mM - - - 647 - - - 
Et2NCS2- 3.1 mM - 0.004 mM - - - 775 nM - - 
PhB(OH)2 23.1 mM 0.077 mM 0.0098 mM - - 300 2357 nM - - 
41 847 nM - 40.1 nM - - - 21.12 - - 
42 824 nM - 80.7 nM - - - 10.21 - - 
43 5100 nM - 54.2 nM - - - 94.09 - - 
19 30 nM - - 40.3 nM 25.2 nM - - - 1.19 nM 
- no selective cause for this enzyme detected so far. 
small molecule inhibitors/anions have been recently obtained 
by our groups and are shown in Table 2. 
2.2.6.1. SmuCA  
SmuCA is inhibited by cyanate, carbonate, stannate, di-
vannadate and diethyldithiocarbamate in the submillimolar 
range (KIsof 0.30–0.64 mM) and more efficiently by sul-
famide, sulfamate, phenylboronic acid and phenylarsonic 
acid (KIs of 15–46 μM) [97] (Table 2). 
2.2.6.2. PgiCAb  
PgiCAb is inhibited by cyanate and diethyldithiocarba-
mate in the submillimolar range (KIs of 0.23–0.76 mM) and 
more efficiently by sulfamide, sulfamate, phenylboronic acid 
and phenylarsonic acid (KIs of 60–78 μM) [86] (Table 2). 
2.2.6.3. PgiCA 
Inorganic anions suchas thiocyanate, cyanide, azide, hy-
drogen sulfide, sulfamate and trithiocarbonate are effective 
PgiCA inhibitors with inhibition constants in the range of 
41–97 μM. Other effective inhibitors are diethyldithiocarba-
mate, sulfamide, and phenylboronic acid, with KIs of 4.0–9.8 
μM [28,
 
91] (Table 2). 
3. SELECTIVE INHIBITORS FOR THE BACTERIAL 
OVER THE HUMAN CA ISOFORMS 
Among the set of 47 sulfonamides/sulfamates investi-
gated as inhibitors of many bacterial (as well as human) 
CAs, few compounds showed selectivity for the inhibition of 
the pathogen over the host enzyme (Table 3). Indeed, most 
of these compounds showed better inhibitory properties 
against the mammalian over the bacterial enzymes. For ex-
ample, against VchCA, the most selective sulfonamide in-
hibitors were BZA, EZA, MZA and 21, which had selectiv-
ity ratios for inhibiting the bacterial enzyme over hCA II in 
the range of 2.14 – 11.6.The Helicobacter enzymes, hpαCA 
and hpβCA, also had several slightly selective inhibitors, 
such as 21 and3, which showed selectivity ratios of 2.04 – 
3.48 against the α-class enzyme and of 2.08 – 2.88 against 
the β-class one. In the case of the two Porphyromonas gin-
givalis enzymes PgiCA and PgiCAb, some isoform selective 
inhibitors were discovered recently. For the γ-class enzyme 
the most selective compounds were diethyldithiocarbamate, 
phenylboronic acid and the newly reported sulfonamides 41-
43, which incorporate new scaffolds. These derivatives 
showed selectivity ratios of 10.2 – 2357 (very good one). On 
the other hand, for the β-class enzyme PgiCAb only pheny-
larsonic and phenylboronic acid showed a good selectivity 
profile over hCA II, with ratios of 300-647. 
CONCLUSION 
In last ten year a multitude of new CAs were detected, 
cloned and characterized in many pathogenic bacteria, such 
as H. pylori, B. suis, V. cholerae, S. tiphimurium, L. pneu-
mophila, S. pneumoniae, M. tuberculosis, C. perfringens, P. 
gingivalis, etc. Enzymes belonging to the α-, β- and/or γ-CA 
classes were detected in these pathogens. Many of these en-
zymes were shown to possess a significant catalytic activity 
for the CO2 hydration reaction, and furthermore, it has been 
demonstrated that in some of these pathogens they are cru-
cial for the life cycle of the bacterium. In vitro inhibition 
studies were performed for many of these enzymes with in-
organic anions, small molecules such as boronic acids, phen-
ylarsonic acid, sulfamic acid, sulfamide, sulfonamides, and 
dithiocarbamates. In many cases effective inhibitors were 
detected, some of which also inhibited the bacterial growth 
in vivo. However, very few of the detected inhibitors were 
also selective for the bacterial over the human, such as hCA 
II isoform. This is in fact one of the main challenges in pro-
posing CAIs as novel anti-infective with a new mechanism 
of action. Some recent work, in which highly selective P. 
gingivalis CA inhibitors (over hCA II) were detected, how-
ever demonstrates that this goal is not an impossible one. In 
fact, by using structure-based drug design processes we es-
timate that it will be possible to achieve the desired selectiv-
ity for inhibiting preferentially the bacterial but not the host 
CA isoforms. 
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